Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX ® ) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
Conclusion
For adult patients with NDO who are not adequately managed with ACHDs, onabotulinumtoxinA + BSC appears to be a cost-effective use of resources in the UK NHS.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Behavioural Therapy | Botox | Clinical Trials | Health Management | Incontinence | Multiple Sclerosis | Neurology | Spinal Cord Injury | UK Health